DDInter1929 DDInter105
Verteporfin, marketed as Visudyne, is a benzoporphyrin derivative. It is used as a photosensitizer in photodynamic therapy to eliminate abnormal blood vessels in wet form macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 nm in the presence of oxygen, produces highly reactive short-lived singlet oxygen and other reactive oxygen radicals, resulting in local damage to the endothelium and blockage of the vessels.
A plasma alpha 2 glycoprotein that accounts for the major antithrombin activity of normal plasma and also inhibits several other enzymes. It is a member of the serpin superfamily.
Verteporfin {u} (Compound) is included by {v} (Pharmacologic Class) Photosensitizing Activity
Verteporfin {u} (Compound) causes {v} (Side Effect) Injection site pain
Verteporfin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Polymyxin B
Verteporfin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lapatinib
Verteporfin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bivalirudin
Verteporfin {u} may lead to a major life threatening interaction when taken with {v} Aminolevulinic acid
Verteporfin (Compound) is included by Photosensitizing Activity (Pharmacologic Class)
Verteporfin (Compound) causes Injection site pain (Side Effect)
Verteporfin may cause a minor interaction that can limit clinical effects when taken with Polymyxin B
Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib
Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with Bivalirudin
Verteporfin may lead to a major life threatening interaction when taken with Aminolevulinic acid